AMAG Pharmaceuticals (AMAG) : During the past 4 weeks, traders have been relatively bearish on AMAG Pharmaceuticals (AMAG), hence the stock is down -9.2% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -6.64% relative to the S&P 500. The 4-week change in the price of the stock is -9.39% and the stock has fallen -7.25% in the past 1 week.
For the current week, the company shares have a recommendation consensus of Buy. The stock has recorded a twenty day Moving Average of 6.14% and the fifty day Moving Average is 4.53%. AMAG Pharmaceuticals, Inc. is up 14.69% in the last three month period. Year-to-Date the stock performance stands at -20.37%.
AMAG Pharmaceuticals (AMAG) : The highest level AMAG Pharmaceuticals (AMAG) is projected to reach is $80 for the short term and the lowest estimate is at $27. The consolidated price target from 6 rating analysts who initiate coverage on the stock is $43.5 and the possibility the share price can swing is $18.88.
AMAG Pharmaceuticals (NASDAQ:AMAG): stock turned positive on Friday. Though the stock opened at $23.98, the bulls momentum made the stock top out at $24.39 level for the day. The stock recorded a low of $23.61 and closed the trading day at $24.04, in the green by 0.08%. The total traded volume for the day was 533,781. The stock had closed at $24.02 in the previous days trading.
AMAG Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses on maternal health, anemia and cancer supportive care. The Company markets Makena (hydroxyprogesterone caproate injection), Feraheme (ferumoxytol) Injection for Intravenous (IV) use and MuGard Mucoadhesive Oral Wound Rinse. Feraheme is an IV iron replacement therapy for the treatment of iron deficiency anemia (IDA) in adult patients with chronic kidney disease (CKD). Feraheme is approved for marketing in the United States. Makena is a drug indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth. MuGard is indicated for the management of oral mucositis/stomatitis and all types of oral wounds, including aphthous ulcers/canker sores and traumatic ulcers, such as those caused by oral surgery or ill-fitting dentures or braces.